Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Dec 26, 2025; 17(12): 115254
Published online Dec 26, 2025. doi: 10.4330/wjc.v17.i12.115254
Published online Dec 26, 2025. doi: 10.4330/wjc.v17.i12.115254
Comparison of beta-blockers vs calcium channel blockers in heart failure with preserved ejection fraction
Moaz Mansoor, Department of Medicine, CMH Lahore Medical College, Lahore 54810, Punjab, Pakistan
Faisal Nabi Depar, Department of Medicine, People’s University of Medical & Health Sciences for Women, Shaheed Benazirabad, Nawabshah 67480, Sindh, Pakistan
Hafiz Usama Talha, Department of Cardiology, Islamic International Medical College, Rawalpindi 00666, Punjab, Pakistan
Haroon Ur Rashid, Department of Neurology, Lady Reading Hospital, Peshawar 25000, Khyber Pakhtunkhwa, Pakistan
Ahmad Ashraf, Department of Medicine, Arif Memorial Teaching Hospital, Lahore 54600, Pakistan
Muhammad Nouman, Department of Internal Medicine, Okara Patient Welfare Association, Okara 56300, Punjab, Pakistan
Mohammad Abbas, Department of Medicine, Khyber Medical College, Peshawar 25120, Khyber Pakhtunkhwa, Pakistan
Maaz Tariq Abbasi, Department of Medicine, Ziauddin University, Karachi 75600, Sindh, Pakistan
Ali Sher, Department of Cardiology, International University of Kyrgyzstan, ISM IUK Eastern Campus, Bishkek 720054, Chüy, Kyrgyzstan
Author contributions: Mansoor M designed the research and wrote the first manuscript; Mansoor M, Depar FN, Talha HU, Rashid HU, Ashraf A, Nouman M, Abbas M, Abbasi MT, and Sher A contributed to conceiving the research and analyzing data; Mansoor M and Sher A conducted the analysis and provided guidance for the research; all authors reviewed and approved the final manuscript.
Institutional review board statement: This study was approved by the Institutional Review Board of Combined Military Hospital Lahore (Ref No. 121/IRB/CMH/L-2025, Date: 16-08-2025).
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: The authors disclose that they have no conflict of interest related to the subject of this study.
Data sharing statement: The simulated dataset generated and analyzed during the current study is available from the corresponding author upon reasonable request. As the data were synthetically derived from aggregated and anonymized electronic medical record distributions, no real patient identifiers were used, and ethical approval or patient consent was not required.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ali Sher, MD, Department of Cardiology, International University of Kyrgyzstan, ISM IUK Eastern Campus, 1F Intergelpo Street, Bishkek 720054, Chüy, Kyrgyzstan. aligondal78679@gmail.com
Received: October 15, 2025
Revised: October 24, 2025
Accepted: November 13, 2025
Published online: December 26, 2025
Processing time: 73 Days and 2.2 Hours
Revised: October 24, 2025
Accepted: November 13, 2025
Published online: December 26, 2025
Processing time: 73 Days and 2.2 Hours
Core Tip
Core Tip: This retrospective analysis demonstrates that beta-blockers may confer potential benefits in reducing all-cause mortality [hazard ratios (HR) 0.78] and heart failure hospitalizations (HR 0.86) compared to calcium channel blockers in patients with heart failure with preserved ejection fraction, though with increased risks of symptomatic bradycardia and drug discontinuation. These findings support personalized pharmacologic strategies, pending validation through prospective trials.